Search

Your search keyword '"Leo I"' showing total 1 results
Start Over Author "Leo I" Region chicago

Refine your results

1 results on '"Leo I"'

1. University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL.

Author

Galanina N, Smith SM, Liao C, Petrich A, Libao B, Gartenhaus R, Westin JR, Cohen KS, Knost JA, Stadler WM, Doyle A, Karrison T, Gordon LI, and Evens AM

Subjects
Adult, Aged, Aged, 80 and over, Benzimidazoles adverse effects, Chicago, Disease-Free Survival, Female, Humans, Lymphoma, Large B-Cell, Diffuse pathology, Male, Middle Aged, Survival Rate, Benzimidazoles administration & dosage, Lymphoma, Large B-Cell, Diffuse drug therapy, Lymphoma, Large B-Cell, Diffuse mortality
Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results